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Abstract
Introduction: Caspofungin treatment is frequently initiated in shock patients. In the present study, we investigated
the influence of hypovolaemic shock requiring fluid loading on the plasma and pulmonary pharmacokinetic
parameters of caspofungin in the pig.
Methods: After being anaesthetised and mechanically ventilated, 12 pigs were bled to induce a two-hour deep
shock and resuscitated using normal saline based on haemodynamic goals. A one-hour infusion of 70 mg of
caspofungin was started at the beginning of the resuscitation period. The lungs were removed four hours after
caspofungin administration. Sixteen animals served as controls without haemorrhage. Caspofungin concentrations
were measured by using high-performance liquid chromatography, and a two-compartment population
pharmacokinetic analysis was performed.
Results: In the shock group, the volume of blood removed was 39 ± 7 mL/kg and a volume of 90 ± 17 mL/kg
saline was infused throughout the resuscitation period. The extravascular lung water index was higher in the shock
group (9.3 ± 1.6 mL/kg vs 5.7 ± 1 mL/kg in the control group; P < 0.01). In the shock group, the median
(interquartile range) maximal plasma concentration was 37% lower than in the control group (21.6 μg/mL (20.7 to
22.3) vs 33.1 μg/mL (28.1 to 38.3); P < 0.01). The median area under curve (AUC) from zero to four hours was 25%
lower in the shock group than in the control group (60.3 hours × μg/mL (58.4 to 66.4) vs 80.8 hours × μg/mL (78.3
to 96.9); P < 0.01), as was the median lung caspofungin concentration (1.22 μg/g (0.89 to 1.46) vs 1.64 μg/g (1.22
to 2.01); P < 0.01). However, the plasma-to-tissue ratios were not different between the groups, indicating that lung
diffusion of caspofungin was not affected after shock followed by fluid loading. Pharmacokinetic analysis showed
that the peripheral volume of distribution of caspofungin and intercompartmental clearance were significantly
higher in the shock group, as was the total apparent volume of distribution.
Conclusions: Hypovolaemic shock followed by fluid loading in the pig results in a significant increase in the
apparent volume of distribution of caspofungin and in a decrease in its plasma and pulmonary exposition.
Although our model was associated with capillary leakage and pulmonary oedema, our results should be
generalised to the septic shock with caution. Future investigations should focus on monitoring plasma caspofungin
concentrations and optimal caspofungin dosing in shock patients.
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Fungal infections are an important cause of mortality in
ICU patients [1]. Moreover, the prevalence of Candida
infections has increased during the past decade or so
[2], and recent data indicate that invasive pulmonary
aspergillosis may be an underestimated opportunistic
fungal infection in ICU patients [3].
Drug pharmacokinetic parameters in ICU patients are
often different from those in healthy patients, notably
because of physiological alterations induced by sepsis
[4-6]. Besides changes in tissue perfusion, protein bind-
ing and clearance, the observed alterations in membrane
permeability and the subsequently required fluid loading
increase the volume of distribution of many drugs,
which results in insufficient dosages of some antibiotics
in a significant proportion of ICU patients [6-8].
Echinocandins such as caspofungin are semisynthetic
lipopeptides with a pathogen-specific mechanism for
noncompetitive inhibition of biosynthesis of the fungus
cell wall enzyme complex 1,3-b-D-glucan [9,10]. Echino-
candins have documented in vivo activity against Can-
dida spp. [11] and Aspergillus spp. [12]. They are
recognised as antifungal agents of choice in ICU
patients [13]. The antifungal activity of echinocandins is
concentration- and time-dependent and the ratio of area
under the curve (AUC) to the minimal inhibitory con-
centration has been shown to be a good descriptor of
their exposure-response relationship [14-16]. Therefore,
the adequacy of the initial dose is an important point in
the efficacy of echinocandins [17]. In the ICU, caspofun-
gin treatment is frequently initiated in patients who pre-
sent with septic shock, which is notably characterised by
hypovolaemia requiring fluid loading for several hours.
The exposition and distribution of caspofungin may be
affected in these patients, resulting in insufficient plasma
and tissue concentrations [18].
The selective study of the impact of hypovolaemic
shock and fluid loading is difficult in ICU patients, who
have many comorbidities that can affect caspofungin
pharmacokinetics, such as renal insufficiency, need for
dialysis, widely variable albumin levels and concomitant
medications. For this reason, in the present study, we
specifically investigated the influence of hypovolaemic
shock followed by fluid loading on the plasma pharma-
cokinetic parameters and the pulmonary diffusion of
caspofungin in a clinically relevant pig model. Our pro-
tocol was designed to mimic, with good reproducibility,
deep hypovolaemic shock followed by resuscitation con-
comitantly with caspofungin administration.
Materials and methods
The study protocol was approved by the ethics commit-
tee of the Institut de médecine tropicale du service de
santé des armées, Marseille, France. Twenty-eight four-
month-old pigs weighing 40 ± 3 kg (mean ± SD) were
studied.
Anaesthesia and monitoring
Since inducing deep, sustained shock is inconsistent
with spontaneous ventilation, the pigs were anaesthe-
tised and mechanically ventilated. After premedication
by intramuscular injection of 2 mg/kg midazolam,
anaesthesia was induced and maintained by an intrave-
nous infusion of midazolam (0.2 mg/kg/hour), fentanyl
(0.01 mg/kg/hour) and pancuronium (0.3 mg/kg/hour).
A normal saline solution (3 mL/kg/hour) was infused
continuously throughout experiment. The animals were
tracheotomised and ventilated with a tidal volume of 10
mL/kg and a fraction of inspired oxygen of 0.5 (Servo
900C ventilator; Siemens-Elema AB, Solna, Sweden).
The respiratory rate was adju s t e dt oo b t a i na na r t e r i a l
partial pressure of carbon dioxide between 35 and 45
mmHg. A 5-French catheter (Edwards Lifesciences,
Irvine, CA, USA) was inserted into the left internal
jugular vein for fluid loading, and another 5-French
catheter was inserted into the left carotid artery for
blood withdrawal and monitoring of mean arterial pres-
sure (MAP). A pulmonary artery catheter (Edwards Life-
sciences) was inserted through the right external jugular
vein into the right pulmonary artery for measurement of
cardiac index (CI). Identification of the CI end point
during the haemorrhage and resuscitation periods was
assessed using the Vigilance Continuous Cardiac Output
Monitor (Baxter, Deerfield, IL, USA). CI values recorded
for analysis were obtained after injection of three 12-mL
boluses of 5% glucose solution between 0°C and 5°C via
a closed system at end inspiration. Mixed venous oxygen
saturation (SVO2) in pulmonary arterial blood was mea-
sured using a CO-oximeter (278 Blood Gas System;
Ciba Corning, Medfield, MA, USA).
Experimental groups
In the shock group (n = 12), the animals were bled
through the carotid catheter (Figure 1). Blood withdra-
wal was started at a rate of 0.8 to 1 mL/kg/minute and
continued until all three of the following end points
were achieved: MAP of 40 to 45 mmHg, decrease in CI
greater than 40% and SVO2 lower than 30%. End points
were maintained for a period of 120 minutes by means
of further bleeding. During the four-hour resuscitation
period, the animals received isotonic saline at a rate of 2
mL/kg/minute. The infusions were stopped when the CI
reached 90% of the baseline value and SVO2 was above
50%, and the infusions were then adjusted to keep these
parameters constant until the animals were killed. At
the beginning of the resuscitation period, the animals
received a one-hour intravenous infusion of 70 mg of
caspofungin acetate (Cancidas; Merck Sharp & Dohme-
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was injected into the right atrium through the proximal
lumen of the pulmonary arterial catheter via a pump-
driven syringe. A second group of animals (n = 16) used
as controls was anaesthetised and ventilated, but they
were not subjected to bleeding and fluid loading. These
animals were also killed four hours after the start of the
caspofungin infusion.
Caspofungin sampling and assay
EDTA-blood samples were drawn through a dedicated
arterial catheter just before and 15, 30, 60 and 90 min-
utes and 2 hours, 3 hours and 4 hours after the caspo-
fungin infusions were started in both groups. Then the
animals were immediately killed, and lung tissue sam-
ples (2 cm × 2 cm × 2 cm) were surgically removed
from nondependent parts of both the lower and upper
lobes after sternotomy. Plasma was obtained by blood
centrifugation at 1,500 g for 15 minutes. Plasma and
lung samples were immediately stored at -80°C. The
remaining lung tissues were used for the determination
of extravascular lung water indexed to body weight
(EVLWI) by using a gravimetric method as previously
described [19]. Caspofungin acetate was kindly provided
by Merck Sharp & Dohme-Chibret. Plasma and lung
caspofungin concentrations were determined by using a
validated high-performance liquid chromatography
method with fluorescence detection [20] after a solid-
phase extraction (Bond Elut™ column; Agilent Technol-
ogies, Santa Clara, CA, USA). Caspofungin and the
internal standard (IS) propranolol were separated on a
LiChrospher column (100 RP-8e (5 μm); Merck Chemi-
cals KGaA, Darmstadt, Germany) using a mobile phase
consisting of acetonitrile and 0.1% trifluoroacetic acid
buffer (200:300 vol/vol) at a flow rate of 1 mL/minute.
The retention times were 6 and 22 minutes for IS and
caspofungin, respectively. The linearity range was 0.3 to
7.5 mg/L (r
2 > 0.998). The lower limit of quantification,
defined as the lowest concentration that could be deter-
mined with a relative error and precision (relative stan-
dard deviation) less than 20%, was 0.3 μg/mL. Intraday
and interday levels of interassay precision were 1.91%
and 4.84% (0.5 μg/mL), 6.94% and 10.4% (3 μg/mL) and
7.84% and 12% (5 μg/mL) for serum samples. The maxi-
mal concentration (Cmax) was measured at the end of
the infusion.
Lung samples were weighed (200 ± 150 mg), homoge-
nised with a 1.5-mL saline solution, ground for 15 min-
utes and centrifuged twice at 10,000 rpm for 10
minutes. The supernatant liquid was separated, and then
the IS solution was added to 1 mL of supernatant liquid.
For calibration, we spiked different caspofungin and IS
concentrations in saline (matrix of pretreatment). Lung
caspofungin concentrations (Ct) were determined four
hours after starting the caspofungin infusion and are
expressed as micrograms per gram of lung tissue. The
tissue-to-plasma ratio for each group was calculated as
R =( Ct/Cp) × 100, where Cp is the caspofungin plasma
concentration at four hours.
Caspofungin pharmacokinetic analysis
The AUC from zero to four hours (AUC0®4h o u r s )w a s
determined using the trapezoidal rule. The concentra-
tion vs time data for both groups were modelled using
the population approach method implemented in
Monolix version 3.1 release 2 software. A two-com-
partment mammillary model was developed and para-
meterised in terms of central volume of distribution of
caspofungin (V1) and elimination clearance of caspo-
fungin (CL), peripheral volume of distribution of cas-
pofungin (V2) and intercompartmental clearance of
caspofungin (Q). The total apparent volume of distri-
bution of caspofungin (Vd) was calculated as V1 + V2.
The interindividual variability (ω) for each parameter
and the residual variability of the model (s)w e r e
estimated.
Anaesthesia 
instrumentation  Haemorrhagic  
shock  Resuscitation  
baseline 
2 hours 
4 hours 
Caspofungin  
infusion 
1 hour 
euthanasia 
Figure 1 Study protocol in the shock group.
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Statistical calculations were performed using the SPSS
15.0 software package (SPSS Inc., Chicago, IL, USA).
The results are expressed as means ± standard devia-
tions (SD) if data were normally distributed or as med-
ians (interquartile ranges). Two-way analysis of variance
for repeated measures was used to analyse the effect of
group and time on MAP. Tukey’s test was used for post
hoc analyses. The Mann-Whitney rank-sum test was
used to compare plasma caspofungin concentrations,
AUC0®4h o u r s , lung caspofungin concentrations (Ct),
plasma-to-tissue ratios and caspofungin population
pharmacokinetic parameters between groups. P ≤ 0.05
was considered statistically significant.
Results
Haemodynamics and lung water
In the shock group, the volume of blood removed was
39 ± 7 mL/kg, and a volume of 90 ± 17 mL/kg of iso-
t o n i cs a l i n ew a si n f u s e dt h r oughout the resuscitation
period (Figure 2). MAP was progressively restored dur-
ing fluid loading and was not different from the control
group from three hours of resuscitation (Figure 3).
EVLWI was higher in the shock group than in the con-
trol group (9.3 ± 1.6 mL/kg vs 5.7 ± 1 mL/kg; P < 0.01).
Caspofungin plasma pharmacokinetics
The caspofungin plasma concentration profile over a
four-hour period in animals in the shock and control
groups is presented in Figure 4. Median Cmax was 35%
lower in the shock group (P < 0.002 vs control group)
(Figure 4 and Table 1), and the caspofungin concentra-
tion remained significantly lower in the shock group
until four hours after caspofungin infusion was started,
resulting in a 25% lower median AUC0®4h o u r s(Table
1). Whereas V1 and CL from the central compartment
were not different between groups, Q, V2 and Vd were
higher in the shock group (Table 2).
Lung caspofungin concentrations
Caspofungin concentrations were not significantly differ-
ent between the lower and upper lung lobes or between
the left and right lungs. Therefore, values from the four
sampled lobes were averaged, and the mean lung con-
centration is reported. We observed a 25% lower median
lung caspofungin concentration in the shock group than
in the control group (Table 1). However, no significant
difference was observed between plasma-to-tissue ratios
in the two groups, indicating that lung diffusion of cas-
pofungin was not affected after shock followed by fluid
loading.
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Figure 2 Time evolution of cumulative fluid loading in the shock group. The results are expressed as means ± standard deviation (SD).
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In ICU patients, septic shock is common and carries a
high mortality rate [21]. In this situation, both the pre-
cocity and adequacy of antimicrobial therapy are major
prognostic factors [22]. The antifungal activity of caspo-
fungin has been shown to be concentration-dependent
in vitro and in vivo [14,15]. Moreover, the adequacy of
t h ei n i t i a ld o s em a yb ea ni m p o r t a n tp o i n ti nt h ee f f i -
cacy of echinocandins [17]. Therefore, it is critical to
administer a sufficient dose, especially in the first days
of treatment. Our results show that hypovolaemic shock
followed by fluid loading in the pig results in a signifi-
cant decrease in early plasma caspofungin exposition, as
reflected by a lower maximal concentration and a lower
AUC0®4h o u r s . Fluid loading was associated with a
decrease in the pulmonary concentration of caspofungin.
In the early clinical development program for caspo-
fungin, a target concentration of 1 μg/mL was used as a
guide for concentrations likely to be efficacious. This
target was determined on the basis of in vitro suscept-
ibility test results and was selected as the concentration
that exceeded the minimal inhibitory concentration at
which 90% of Candida spp. isolates were inhibited [23].
In healthy humans, a single dose of 70 mg resulted in a
mean plasma Cmax of 12.04 μg/mL (95% confidence
interval, 10.87 to 13.33) and a concentration at 24 hours
(trough concentration) of 1.42 μg/mL (95% confidence
interval, 1.18 to 1.71) with linear plasma pharmacoki-
netics [24]. On the basis of these studies, a once-daily
dosing regimen of 50 mg was considered adequate for
efficacy in the treatment of fungal infections. However,
a loading dose of 70 mg is recommended, since trough
caspofungin plasma concentrations fell below the target
concentration of 1 μg/mL for the first two days of
administration in the absence of a loading dose.
The pharmacokinetics of caspofungin have been
recently studied in a cohort of surgical ICU patients
[18]. In that study, caspofungin exhibited wide variations
in 24-hour trough plasma concentrations during the
whole treatment period. Although the mean trough con-
centration at day 2 of treatment was slightly higher than
reported in healthy humans [21] and exceeded 1.0 μg/
mL in 75% of patients, it failed to reach this target con-
centration in 25% of them [18]. Therefore, the authors
concluded that a dose adjustment may be necessary in
some ICU patients, based on the monitoring of plasma
concentrations. Although 29 of the 40 included patients
received vasopressors for shock, neither the need for
fluid loading nor its impact on caspofungin pharmacoki-
netics was reported [18]. The authors attributed the
variability of caspofungin pharmacokinetics not only to
the effect of supportive therapies such as fluid loading,
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Figure 3 Mean arterial pressure in the control group (squares) and shock group (circles) at baseline and after 30 minutes and 120
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Page 5 of 9haemodialysis and catecholami n e sb u ta l s ot op a t i e n t -
specific parameters such as albuminaemia, organ dys-
function and weight. In the present study, we specifically
evaluated the effect of hypovolaemic shock requiring
large fluid loading with a positive fluid balance exceed-
ing 50 mL/kg. Our observed decrease in plasma and
pulmonary caspofungin exposition in this situation
points out that this factor may largely contribute to the
underdosing reported in ICU patients [18]. Since the
volume of distribution of echinocandins is likely to
correspond to the extracellular volume [25], the massive
fluid loading required to restore and maintain haemody-
namics observed in the present study or in shock
patients in general is likely to be responsible for the
increase in V2 and Vd as well as in the subsequent
decrease in caspofungin’s early plasma and tissue con-
centrations. Whether a subsequent modification of CL
would affect its pharmacokinetics in this situation
requires further studies. Notably, the haemodynamic
failure observed while initiating treatments such as
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Figure 4 Caspofungin concentration time profile in the shock group (white plots) and in the control group (grey plots).E a c hp l o t
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Table 1 Caspofungin pharmacokinetic parameters in plasma and lung tissue
Shock group (n = 12) Control group (n = 16)
Caspofungin parameters Median IQR Median IQR P value
Plasma
Cmax (μg/mL) 21.6 20.7 to 22.3 33.1 28.1 to 38.3 0.002
AUC0®4 hours (μg/hour/mL) 60.3 58.4 to 66.4 80.8 78.3 to 96.9 0.009
Cp (μg/mL) 16.1 12.5 to 17.4 20.7 17.4 to 23.1 0.007
Lung tissue
Ct (μg/g) 1.22 0.89 to 1.46 1.64 1.22 to 2.01 0.001
Ratio (%) 7.76 6.41 to 9.42 7.28 6.2 to 9.5 0.862
AUC0®4 hours: area under the curve of caspofungin plasma concentration from zero to four hours; Cmax: maximum caspofungin concentration; Cp: caspofungin
plasma concentration at four hours; Ct: lung caspofungin concentration at four hours; IQR: interquartile range. Ratio = (Ct/Cp) × 100; P values are for shock group
vs control group.
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marked than in our present study [26]. Therefore, it is
possible that caspofungin concentrations during the first
days of treatment may be insufficient in a significant
number of ICU patients with marked haemodynamic
instability [18,27].
With regard to lung tissue concentrations, our
observed decrease in plasma concentration had a direct
impact on pulmonary concentrations measured four
hours after administration. These data signify that insuf-
ficient initial plasma concentrations may result in low-
ered concentrations at the site of the infection. As is
true during sepsis, our model was characterised by lung
oedema and inflammation [19], which did not affect the
pulmonary diffusion of caspofungin or influence its dis-
tribution to the different lung lobes.
Our study has several limitations. First, we used a hae-
morrhagic shock model rather than an invasive fungal
infection model. Animal models of invasive candidiasis
or aspergillosis [28] are mainly used to study the efficacy
of antifungal therapies. However, these models do not
induce hypovolaemic shock such as required for the
present study. A commonly used model of sepsis is lipo-
polysaccharide (LPS) injection [29], which reproduces
bacterial sepsis. This model may be more representative
than haemorrhagic shock of the capillary leakage
observed during human sepsis and could have different
influences on the distribution of caspofungin. However,
this model has unpredictable effects on pharmacoki-
netics, since haemodynamic effects are very variable and
pathophysiological changes caused by LPS administra-
tion can potentially affect all aspects of drug metabolism
[29]. Moreover, our model is also characterised by capil-
lary leakage and vascular failure, as attested by
requirements for fluid loading and the observed increase
in lung water. Second, we did not study the long-term
pharmacokinetics of caspofungin, since our model is
inconsistent with a prolonged survival of the animals
without other therapeutic interventions. Considering the
pharmacokinetic linearity of caspofungin [24], the
decrease in caspofungin concentrations that we observed
is likely to affect trough plasma and tissue concentra-
tions. However, further studies are required to clarify
whether tissue concentrations may be lowered during
the course of several days. Indeed, therapeutic concen-
trations of caspofungin have been shown to persist at
the site of infection well after serum concentrations fall
below the minimal inhibitory concentration, and the
terminal half-life of this drug has been suggested to be
heavily influenced by the accumulation of caspofungin
in tissues [28]. Third, we did not study which dose of
caspofungin would result in similar exposition in shock
and control animals. Recently, the use of higher caspo-
fungin doses has been shown to be safe in healthy adults
and could be evaluated in ICU patients [30]. Finally, we
did not measure caspofungin concentrations in other
tissues. However, lung concentrations of caspofungin
are representative of those measured in various organs
[31].
Conclusions
The present study shows that hypovolaemic shock
requiring a massive fluid loading is responsible for a
marked decrease in plasma and pulmonary caspofungin
early exposition. Although our results are insufficient to
recommend higher caspofungin doses in septic shock
patients, they warrant for clinical studies to define the
optimal dosing of caspofungin at the initial stage of fun-
gal sepsis and to assess the usefulness of its concentra-
tion monitoring.
Key messages
￿ Hypovolaemic shock requiring massive fluid load-
ing is responsible for a marked decrease in plasma
and pulmonary caspofungin early exposition.
￿ Lung diffusion of caspofungin was not affected in
these conditions.
￿ Investigators in future studies should study the
optimal dosing of caspofungin at the initial stage of
fungal sepsis and the usefulness of monitoring its
concentration.
Abbreviations
σ: residual variability of the model; ω: interindividual variability; AUC0®4 hours:
area under the curve of caspofungin plasma concentration from zero to four
hours; CI: cardiac index; CL: elimination clearance of caspofungin; Cmax:
maximal plasma concentration of caspofungin; Cp: caspofungin plasma
concentration at four hours; Ct: lung caspofungin concentration at four
hours; EVLWI: extravascular lung water indexed to body weight; MAP: mean
Table 2 Caspofungin population pharmacokinetic
parameters in plasma
Shock group
(n = 12)
Control group
(n = 16)
Caspofungin parameters Estimate RSE (%) Estimate RSE (%)
CL (L/hour) 0.21 26 0.29 20
V1 (L) 0.96 45 0.98 24
Q (L/hour) 8.16* 39 4.23 30
V2 (L) 2.8* 15 1.43 12
Vd (L) 3.9* - 2.5 -
ω (CL) (%) 25 21 75 39
ω (V1) (%) 10 37 80 36
ω (Q) (%) 10 32 54 35
ω (V2) (%) 10 35 19 34
s (%) 28 13 34 8
CL: central elimination clearance; Q: intercompartmental clearance; RSE:
relative standard error;
V1: central volume of distribution; V2: peripheral volume of distribution; Vd:
total apparent volume of distribution; s: residual variability of the model; ω:
interindividual variability. *P < 0.05 vs control group.
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Page 7 of 9arterial pressure; Q: intercompartmental clearance of caspofungin; SVO2:
mixed venous oxygen saturation; V1: central volume of distribution of
caspofungin; V2: peripheral volume of distribution of caspofungin; Vd: total
apparent volume of distribution of caspofungin.
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